Angiozyme

From WikiMD's WELLNESSPEDIA

Angiozyme, also known as RPI.4610, is an advanced anti-angiogenic ribozyme that has garnered significant attention in the field of oncology, specifically for the treatment of kidney cancer. Ribozymes are RNA molecules that have catalytic activity, and in the context of Angiozyme, it has been tailored to prevent angiogenesis, the process of new blood vessel formation. By inhibiting angiogenesis, the growth and progression of tumors can potentially be halted since tumors rely on new blood vessels for their growth and metastasis.

Overview[edit]

  • Type: Anti-angiogenic ribozyme
  • Other Names: RPI.4610
  • Main Use: Treatment of kidney cancer

Mechanism of Action[edit]

Angiozyme operates by interfering with the vascular endothelial growth factor (VEGF) receptor. The VEGF receptor is integral in the process of angiogenesis. By inhibiting this receptor, Angiozyme might halt the growth of new blood vessels that tumors require for nourishment and growth.

Clinical Studies[edit]

Extensive studies and clinical trials are being conducted to determine the efficacy of Angiozyme in treating kidney cancer. Early observations indicate:

  • Efficacy: The potential of halting or slowing down the growth of kidney tumors.
  • Side Effects: Preliminary tests have suggested that Angiozyme exhibits no significant side effects, which can make it a promising agent in cancer therapy, provided its therapeutic efficacy is conclusively demonstrated.

Drug Classification[edit]

Angiozyme falls under the drug families of:

Future Prospects[edit]

While the current findings on Angiozyme are promising, further long-term studies are required to fully understand its potential and limitations. If proven effective, it can be a valuable addition to the arsenal of drugs available for kidney cancer treatment, especially given its reportedly minimal side effects.

See also[edit]

External links[edit]

  • Angiozyme entry in the public domain NCI Dictionary of Cancer Terms
Stub icon

This oncology article is a stub. You can help WikiMD by expanding the page.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Angiozyme&oldid=6531643"